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Rosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor (PPAR)-γ, has been recently
described as possessing antitumoral properties. We investigated RGZ effect on cell proliferation in two cell line models (SW13
and H295R) of human adrenocortical carcinoma (ACC) and its interaction with the signaling pathways of the activated IGF-I
receptor (IGF-IR). We demonstrate a high expression of IGF-IR in the two cell lines and in ACC. Cell proliferation is stimulated
by IGF-I in a dose- and time-dependent manner and is inhibited by RGZ. The analysis of the main intracellular signaling
pathways downstream of the activated IGF-IR, phosphatidyl inositol 3-kinase (PI3K)-Akt, and extracellular signal-regulated kinase
(ERK1/2) cascades reveals that RGZ rapidly interferes with the Akt and ERK1/2 phosphorylation/activation which mediates IGF-I
stimulated proliferation. In conclusion, our results suggest that RGZ exerts an inhibitory effect on human ACC cell proliferation
by interfering with the PI3K/Akt and ERK1/2 signaling pathways downstream of the activated IGF-IR.
Copyright © 2008 Giulia Cantini et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Adrenocorticalcarcinoma(ACC) is a rare tumor with an
incidence of approximately 1-2 per million population per
year. ACC is a very aggressive tumor, characterized by a poor-
prognosis: approximately 50% of patients do not survive
beyond 2 years from the diagnosis and the 5-year mortality
rate is between 20% and 60% [1]. Its poor prognosis depends
mainly upon the limited therapeutic resources. At present,
a complete surgical removal following an early diagnosis is
the only valuable option for the tumor’s cure. Moreover,
other than improved surgical management, the prognosis
for ACC has not changed significantly over the past three
decades [2]. The tumor is, in fact, resistant to radio- and
chemotherapy and medical treatment very rarely leads to a
complete remission in the case of recurrences or metastatic
spread. Although several new medical therapeutic options
have been recently proposed [3], at present the medical
treatment of advanced ACC is far from being satisfactory,
due to our poor knowledge of the molecular mechanisms
leading to malignant transformation of adrenocortical cells.
In fact, although some intracellular signaling pathways have
been shown to be altered in ACC cells [4], efforts to identify
the events leading to neoplastic transformation and tumor
invasiveness have met with limited success. The role of IGF-I
system in mediating proliferation and progression has been
well documented in several cancers, including adrenocortical
carcinoma [5]. In particular, ACC, as well as the H295R cell
line [6], overexpress both IGF-II [7] and its promiscuous
receptor IGF-IR [8] in comparison to adrenal adenomas and
normal adrenal tissue. The overexpressed IGF-II is thought
to act in a paracrine fashion through the IGF-IR to sustain
tumor and cell proliferation [6, 9, 10].
Peroxisome proliferator activated receptor (PPAR)-γ is
a ligand-activated transcriptor factor and a member of the
nuclear hormone receptors superfamily. Thiazolidinediones
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(TZDs), which are a family of PPAR-γ ligands, have been
introduced in the therapy of type 2 diabetes mellitus (T2D)
because of their ability to reduce insulin resistance. In
the last few years, an increasing amount of experimental
data showing the ability of these drugs to exert additional
pleiotropic actions such as regulation of inflammatory
processes and of cancer cell growth has been published [11].
TZD effects seem to be mainly due to their ability to bind
and activate PPARγ differentially expressed in adipose and
other tissues. Upon ligand binding, PPARγ heterodimerizes
with the 9-cis retinoic acid receptor (RXR) on specific
responsive elements in the promoters of genes involved
in glucose and insulin homeostasis, lipid metabolism, and
cellular differentiation. Besides this transactivating activity,
a ligand-dependent transcriptional transrepression mecha-
nism involving PPARγ/RXR complex has been described.
According to such a model, the heterodimerized receptor
represses gene transcription in a DNA-binding independent
way by physically sequestering activated transcriptional fac-
tors or their coactivators [12]. More recently, an increasing
number of TZD effects, and in particular the antineoplastic
ones, have been shown to be independent of PPARγ activity
[13]. Finally, rapid nongenomic activities of TZDs, not
resulting in modulation of gene transcription but affecting
posttranslational modifications involved in cell signaling,
have been reported [14].
In addition to their action as insulin sensitizers, TZDs
inhibit cell growth in breast, colon, prostate, lung, pancreas,
stomach, thyroid, liver and adrenal cancers [15]. However,
the molecular mechanisms underlying such pharmacological
activities remain to be elucidated.
Rosiglitazone (RGZ) and pioglitazone (PGZ), the two
most widely used PPARγ agonists, have been shown to
inhibit growth and invasiveness of the human adrenal cancer
cell line H295R [16] as well as to induce cell differentiation
and apoptosis [10]. Moreover, H295R cells and both normal
and tumoral adrenal tissue express PPARγ, with no differ-
ences in the level of expression between tumoral and normal
tissue and no correlation with clinical parameters such as
tumor size, hormonal profile, and so forth [10, 16].
In this study, we investigate two different cell models of
ACC, namely, SW13 and H295R lines, whether the TZD RGZ
may exert its antiproliferative action on human ACC cell
lines by interfering with the intracellular pathways activated
by IGF-IR.
2. MATERIALS AND METHODS
2.1. Reagents
Anti-phospho [Akt (Ser473), ERK1/2 (T202/Y204)] and
anti-Akt antibodies were from Cell Signaling Technology,
Inc. (Danvers, Mass, USA). Anti-ERK1/2, anti-IGF-IRβ, and
anti-actin antibodies were from Santa Cruz Biotechnology,
Inc. (Santa Cruz, Calif, USA). Anti-PI3K p85 regulatory
subunit antibody was from Upstate Biotechnology (Lake
Placid, NY, USA). Rosiglitazone was from Alexis Biochem-
icals (San Diego, Calif, USA). MTS solution was purchased
from Promega (Madison, Wis, USA). IGF-I was from
Sigma Aldrich (San Louis, Mo, USA). [Methyl-3H]thymidine
([3H]TdR) was purchased from NEN Life Science Products
(Boston, Mass, USA). NVP-AEW541 was provided by Novar-
tis (Basel, Switzerland).
2.2. Tissue specimens and cell cultures
A total of three normal human adrenal glands, three adrenal
carcinomas, and three adenomas were used in this study.
Normal adrenal glands were removed during an expanded
nephrectomy due to renal carcinoma or from organ donors
(age 32–72 years). Approval for the use of human material
was given by the Local Ethical Committee. Informed consent
was obtained from each patient. Adrenocortical fragments,
collected immediately after surgery, were snap frozen in
liquid nitrogen and stored at −80◦C.
The human ACC cell lines H295R and SW13 were
obtained from the American Type Culture Collection
(Manassas, Va, USA). SW13 were cultured in DMEM/F-12
medium (Sigma-Aldrich) with 10% FBS (Euroclone), 2 mM
L-glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin. H295R need DMEM/F-12 medium enriched with
a mixture of insulin/transferrin/selenium (Sigma-Aldrich).
Cells were incubated at 37◦C in a humidified 5% CO2
atmosphere.
Subconfluent cells starved 24 hours were treated with
different stimuli added to serum-free medium. Rosiglitazone
was added simultaneously with IGF-I, at the doses and for
the time intervals (15 minutes for western blot analysis and
from 24 hours up to 7 days for proliferation experiments)
indicated in figure legends.
Cells were pretreated 1 hour with NVP-AEW541 before
addition of other stimuli. For incubations longer than 24
hours, media and stimuli were replaced every day.
2.3. MTS assay
SW13 and H295R were seeded in 96-well plates at the
density of 3·103 and 8·103 cells/well, respectively. After
24-hour starvation in serum-free (SF) medium, cells were
treated with the different stimuli in SF medium for the
indicated times (see figure legends) and cell number in each
well was evaluated by MTS assay (Promega), according to
the manufacturer’s instructions. The samples were analyzed
by an ELISA plate reader (Wallac 1420 - PerkinElmer) at
490 nm wavelength to measure optical density (OD). Each
experimental point was performed in quintuplicate in at least
three independent experiments.
2.4. Cell proliferation assays
2.4.1. Viable cell counting
Cells were seeded in 12-well plates (1,8·104 and 5·104
cells/well for SW13 and H295R, resp.), and after 24-hour
starvation were treated for 2 or 4 days in SF medium,
then trypsinizedand counted in the haemocytometer. Mean
cell number was obtained by counting triplicate in three
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different experiments. Dead cells were excluded by trypan
blue exclusion test.
2.4.2. DNA synthesis assay: [3H]thymidine uptake
DNA synthesis was evaluated according to the amount
of [3H]TdR incorporated into trichloroacetic acid (TCA)-
precipitated materials. Cells seeded at different density
(5·104 or 2,5·104 H295R cells/well in 12 or 24 well plates, and
1,8·104 SW13 cells/well in 12 well plates) were grown in 10%
FBS complete medium till 70% confluence. After 24-hour
starvation, cells were treated with IGF-I or RGZ in 1% FBS
medium for the indicated times (1–7 days) pulsing them with
1.0 μCi/ml [3H]TdR (6.7 Ci/mmol) 4 hours before stopping
proliferation in ice-cold 10% TCA. After washing in TCA
and then in methanol, cells were solubilized in 0.2 N NaOH,
and radioactivity was measured in the scintillation counter.
Experiments were performed in triplicate and repeated at
least three times.
2.5. Western blot analysis
Treated cells were extracted in lysis buffer (20 mM Tris,
pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM Na3VO4,
1 mM PMSF). Thirty μg of proteins measured by Coomassie
reagent (BIO-RAD Labs, Hercules, Calif, USA) were loaded
onto 8–10% reducing SDS-PAGE. After separation, pro-
teins transferred to nitrocellulose membranes were 1 hour
blocked at room temperature in 5% skimmed milk in
TTBS (0.1% Tween-20, 20 mM Tris, 150 mM NaCl) and
incubated overnight with primary antibodies at appropriate
dilutions followed by peroxidase-secondary IgG (1:3000).
Proteins were revealed by BM-enhanced chemiluminescence
system (Roche Diagnostics, Milan, Italy). Image acquisition
anddensitometric analysis were performed with Quantity
One software on a ChemiDoc XRS instrument (BIO-RAD
Labs, Hercules, Calif, USA). All western blots were repeated
in at least 3 independent experiments. Membrane re-probing
was performed after stripping procedure (Pierce, Rockford,
Il, USA).
PI3 kinase assay
Treated cells were extracted in lysis buffer A (20 mM Tris, pH
7.4, 137 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1% NP-40,
1 mM Na3VO4, 1 mM PMSF). After protein measurement,
aliquots containing equal amount of proteins (300 μg) were
precleared with 50 μl of Protein G-Sepharose. Precleared
lysates were then immunoprecipitated overnight at 4◦C with
3 μg of rabbit anti-p85 PI3K antibody in the presence of 50 μl
of Protein A-Sepharose. Sepharose beads washed in a 10 mM
Tris-HCl (pH 7.4) containing 0.1 mM EGTA and 5 mM LiCl,
were suspended in a kinase buffer (10 mM Tris-HCl, 150 mM
NaCl, 5 mM EDTA) containing 20 μg of L-α-phosphatidyl
inositol (Sigma-Aldrich, St. Louis, Mo, USA), 25 mM MgCl2
and 10 μCi of [γ32P]ATP and incubated for 20 minutes at
room temperature. The reaction was stopped by the addition
of 60 μl of 6 M HCl + 160 μl of chloroform:methanol (1:1).
Lipids were then resolved by thin layer chromatography
plates (TLC silica gel 60) (Merck Laborchimica, Florence,
Italy) in chloroform, methanol, water and ammonium
hydroxide (60:47:11, 3:2). Dried TLC sheets were developed
by autoradiography. Band quantification was performed
with ChemiDoc XRS instrument (BIO-RAD Labs, Hercules,
Calif, USA).
2.6. Statistical analysis
Results are expressed as mean ± SE. The effect of different
concentrations of IGF-I and RGZ on cell proliferation was
tested by One-Way ANOVA. Multiple Post Hoc comparisons
were performed by Bonferroni’s correction. Student’s τ-test
for paired or unpaired data was applied when appropriate
for comparison of two sets of data. P < .05 was taken as
significant.
3. RESULTS
Adrenal cancer is characterized by an increased expression
of the IGF-IR compared to both nontumoral and adenomal
adrenal tissues as demonstrated by western blot analysis
with a specific antibody against the β subunit of IGF-IR
(Figure 1(a)). A marked expression of this receptor isalsop-
resent in SW13 and in particular in H295R adrenocortical
cancer cells (Figure 1(a)), suggesting that both tissue and cell
systems may be highly responsive to the effects of IGF-I and
IGF-II.
In order to study the role of IGF-IR and of its down-
stream intracellular signaling pathways on cell proliferation,
we stimulated both SW13 and H295R cells with increasing
concentrations of the receptor’s elective ligand, IGF-I. IGF-
I is able to induce cell proliferation in a time- and dose-
dependent manner as demonstrated by evaluating cell via-
bility through MTS assay in both SW13 (Figure 1(b)) and
H295R (Figure 1(c)) cells stimulated with increasing concen-
trations of IGF-I (1 to 50 nM) for 24 hours up to 7 days. Such
a stimulatory effect is confirmed by [3H]thymidine uptake
experiments in H295R cells (Figure 1(d)).
Following 24-hour treatment, RGZ reduces cell via-
bility in a dose-dependent manner in SW13 cells treated
(Figure 2(b)) or not (Figure 2(a)) with 10 nM IGF-I, show-
ing an IC50 of 22.48 ± 1.54 μM (coefficient of variation
6.9%) as calculated with ALLFIT program [17], Figure 2(c).
Interestingly, the IC50s derived fromthe two RGZ dose
response viability curves obtained for IGF-I-treated and
untreated cells are not statistically different, suggesting that
the effect of RGZ is similar independently of exogenous
IGF-I stimulation. Thus, we chose to use 20 μM RGZ in
all the experiments. The inhibitory effect of RGZ on cell
proliferation in basal conditions is significantly increased
with the time of incubation as evaluated by [3H]thymidine
uptake experiments in both SW13 (Figure 2(d)) and H295R
(Figure 2(e)) cells. Again, thenegativeeffect on cell viability
exerted by RGZ is similar in IGF-I treated and untreated
SW13 cells (Figures 3(a)–3(e)). Conversely, in H295R cells
where the effect of RGZ requires longer times to become
evident, RGZ is also able to revert IGF-I-stimulation (Figures
3(f)–3(h)). Both IGF-I-stimulated proliferation and the
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Figure 1: Adrenocortical cancer is responsive to IGFs. (a) Western blot analysis of adrenocortical tissues (adrenocortical carcinoma: ACC;
normal adrenal tissue: NOR; adrenocortical adenoma: ADE) and adrenocortical cancer cell lines (SW13 and H295R) reveals a high
expression of IGF-IR in cancer tissue and cells and lower levels in normal and adenoma tissues. Western blot for actin was performed
for lane protein normalization. Molecular weight (Mw) markers are indicated. The effects of cell incubation with increasing doses of IGF-
I (1, 10 and 50 nM) for the indicated times on cell proliferation were evaluated by MTS in SW13 (b) and H295R (c) and confirmed in
H295R by evaluation of [3H]TdR incorporation in cell DNA content (d). Data represent mean ± SE OD (b), (c) or mean ± SE of [3H]TdR
incorporation (counts per minute, cpm) (d). Statistical significance versus respective control: ∗P < .05, ◦P < .01, §P < .005, #P < .001.
inhibitory effect of RGZ are confirmed by SW13 (Figure 3(i))
and H295R (Figure 3(j)) cell counting at 2- and 4-day
incubation, respectively.
To elucidate the intracellular mechanism by which RGZ
affects adrenal cancer cell proliferation, we investigated the
effects of the drug on the two main intracellular signaling
pathways engaged by the activated IGF-IR, namely, the
phosphatidyl inositol 3 kinase (PI3K)-Akt cascade and the
extracellular signal-regulated (ERK) signaling [18].
Rapid stimulation(15 minutes)ofSW13 (Figure 4(a)) and
H295R (Figure 4(b)) cells with 10 nM IGF-I determines
an increased phosphorylation of Akt in Ser473, resulting
in the activation of the enzyme (Figure 4, upper and
lower panels). Concomitant addition of 20 μM RGZ for
15 minutes in the presence or absence of IGF-I interferes
with Akt phosphorylation/activation in SW13 (Figure 4(a))
and H295R (Figure 4(b)) cells. The inhibitory effect of
RGZ is statistically significant versus IGF-I only, but this
trend is also present on active Akt in basal conditions
(Figure 4 lower panels). The in vitro immunokinase assay
for PI3K performed on SW13 (Figure 5(a)) and on H295R
(Figure 5(b)) lysates demonstrates a rapid activation (15
minutes) of the enzyme by IGF-I, which is reverted by
co-incubation with RGZ. The inhibitory effect of RGZ is
evident in basal conditions in H295R cells only (Figures
5(a), 5(b)). Similarly, RGZ interferes with IGF-I-rapid stim-
ulation of phosphorylation/activation of ERK1/2 in SW13
(Figure 6(a)) and H295R (Figure 6(b)), but, conversely, the
effect of RGZ in basal conditions is evident in SW13 cells only
(Figures 6(a), 6(b)).
In order to further demonstrate the involvement of Akt
and ERK signaling downstream of the IGF-IR in medi-
ating cell proliferation, we use the NVP-AEW541 (NVP)
inhibitor of the IGF-IR tyrosine kinase activity. As shown
in Figure 7(a), NVP is able to block phosphorylation of Akt
(upper panel) and ERK1/2 (middle panel) both in the basal
conditions and following 15-minute IGF-I stimulation. The
block of the IGF-IR system by NVP results in inhibition
of IGF-I-stimulated cell proliferation evaluated at 2 and
4 days of treatment in SW13 (Figure 7(b)) and H295R,
respectively, (Figure 7(c)). Moreover, a further addition of
RGZ to the inhibitor results in no significant reduction of
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Figure 2: Dose dependent effects of RGZ on adrenocortical carcinoma cell proliferation. The dose dependent effect of RGZ on SW13 cell
proliferation was evaluated by MTS assay at 48-hour stimulation in the absence (a), (c) or presence (b) of 10 nM IGF-I. A complete dose
response curve for RGZ (10−3 to 2·102 μM) on cell proliferation in SW13 is reported (c), showing the IC50 for RGZ calculated by ALLFIT
program [17]. Data represent mean± SE percentage of OD over controls (RGZ 0 μM). Statistical significance versus respective control (RGZ
0 μM): ∗P < 0.05, #P < 0.001. The time dependent effect of RGZ administration (20 μM) on cell proliferation was evaluated at the indicated
times in SW13 (d) and H295R (e) by [3H]TdR incorporation. Data represent mean± SE percentage of cpm over untreated control. Statistical
significance versus respective Ctrl: ◦P < 0.01, §P < 0.005, #P < 0.001.
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Figure 3: IGF-induced cell proliferation is differently affected by RGZ in SW13 and H295R cell lines. SW13 (a)–(e) and H295R (f)–(h)
proliferation was evaluated by MTS assay following stimulation with increasing doses of IGF-I in the presence or absence of 20 μM RGZ
for the indicated times. Mean ± SE percentage of OD over respective control. Statistical significance: ∗P < 0.05, §P < 0.005, #P < 0.001
versus the corresponding points with RGZ, n = 6. Total number/well of SW13 (i) and H295R (j) cells treated with 10 nM IGF-I and 20 μM
RGZ for 2 and 4 days, respectively, was evaluated by cell counting under optical microscope. Data are expressed as mean ± SE of cell number
evaluated in triplicate in three independent experiments. ◦P < .01, #P < .001 versus Ctrl; ∗P < .001 versus IGF-I.
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Figure 4: RGZ blunts IGF-I stimulation of Akt phosphorylation/activation. Western blot analysis of SW13 (a) and H295R (b) cell lysates
following 15-minutestimulation with 10 nM IGF-I and 20 μM RGZ, reveals an increased phosphorylation of Akt in Ser473 following IGF-I,
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Figure 5: RGZ inhibits IGF-I stimulated PI3K. PI3K activity in SW13 (a) and H295R (b) treated or not for 15 minutes with 10 nM IGF-I and
20 μM RGZ was evaluated by an in vitro assay after immunoprecipitation with an antibody against the PI3K regulatory subunit p85. The
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cell proliferation in the presence of IGF-I compared to NVP
+ IGF-I (Figures 7(b), 7(c)) suggesting that RGZ growth
inhibition is mediated via IGF-IR signaling.
Finally, we investigated whether RGZ could affect not
only the downstream signaling of IGF-IR, but also the levels
of the receptor itself. Figure 8 shows that the IGF-IR levels do
not change following up to 4-day stimulation of SW13 (a) d
H295R (b) cells with 20 μM RGZ.
4. DISCUSSION
Although adrenocortical carcinomas are very rare tumors,
they are very aggressive and highly resistant to chemo- and
radiotherapy. Moreover, the use of the adrenolytic agent,
mitotane (o,p-DDD), is the only medical therapy available
at present. Thus, a better knowledge of the molecular
mechanisms underlying the tumor growth and progression
is mandatory in order to develop more selective and specific
treatments.
Recently, PPARγ ligands have been described as suppress-
ing tumor cell proliferation as well as inducing apoptosis
and a more differentiated phenotype in several types of
cancers [15], including adrenocortical carcinoma [10, 16],
thus suggesting the use of these drugs as a potential new
anticancer therapy. However, all these studies have been
performed either in vivo, on animal models, or in vitro, on
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Figure 6: RGZ dampens IGF-I stimulated ERK1/2 phosphorylation. Western blot analysis of SW13 (a) and H295R (b) cell lysates following 15-
minutes stimulation with 10 nM IGF-I and 20 μM RGZ, reveals an increased phosphorylation of ERK1/2 following IGF-I, which is reverted
by RGZ. Lane protein normalization for ERK1/2 is shown in the middle panels. Molecular weight markers are indicated. Mean ± SE of
phospho-ERK1/2 band intensity over respective Ctrl is shown in 3 independent experiments for SW13 (a) and H295R (b) cells (lower
panels). ∗P < 0.05 versus respective Ctrl; ◦P < .05 and #P < .005 versus IGF-I.
human cancer cells. Moreover, these anticancer effects have
been observed with concentrations of PPARγ agonists which
are not only higher than the clinical doses used for T2D
treatment but also affect PPAR α and δ isoforms, being no
longer selective for PPARγ. However, treatment with RGZ
doses higher than the therapeutical 8 mg/die has been well
tolerated and did not result in any increase in the percentage
of adverse events compared to the placebo group in a double-
blind clinical trial [19].
At present, only three papers address the effects of
PPARγ ligands in ACC using H295R cells as an in vitro
model [10, 16, 20]. Both RGZ and pioglitazone (PIO),
the most used PPARγ TZD ligands, inhibit cell growth by
affecting key cell cycle elements and inducing apoptosis
[10, 16], also dampening cell invasiveness through reduction
of metalloproteinase 2 (MMP2) expression and activity [16].
Moreover, in these cells, RGZ and PIO induce a more
differentiated phenotype where steroidogenesis is increased
due to a significant upregulation of MC2-R and Star
expression [10].
In this paper, we use two different cell models of ACC,
H295R, and SW13. H295R cells retain the ability to synthe-
size steroid hormones, while SW13, derived from a stage IV
tumor, do not, thus suggesting them to be less differentiated
than H295R. Both cell lines seem to be suitable models for
studying the effects of RGZ on IGF-I/IGF-IR axis, since they
express high levels of the IGF-IR, similarly to ACC tissue.
In order to stimulate IGF-IR and its downstream signaling
cascade, we added to the cells increasing concentrations of its
elective ligand, IGF-I. Indeed, IGF-IR binds IGF-I with a 15-
fold higher affinity than IGF-II [21]. However, H295R cells
have been described as producing high levels of IGF-II, which
acts in an autocrine-paracrine loop stimulating the IGF-IR
axis even in basal conditions [8]. For this reason, in our
experimental procedure, we changed cell incubation media
every day to remove the endogenously produced IGF-II thus
making the receptor more responsive to the exogenously
added IGF-I.
In this condition, IGF-I was able to stimulate cell pro-
liferation in a dose- and a time-dependent manner in both
cell models through activation of the two main downstream
intracellular signaling cascades involving phosphatidyl inos-
itol 3-kinase (PI3K)-Akt and extracellular signal-regulated
kinase (ERK1/2) [21], as described also for other tumors
[18]. However, these two pathways are already active even in
basal conditions, as demonstrated by the rather high levels
of ERK and Akt phosphorylation as well as of PI3K activity
found in the absence of IGF-I stimulation, probably due to
the paracrine-autocrine effects of endogenously produced
IGF-II [8].
RGZ has been demonstrated to impair IGF-I system both
in vivo and in vitro by reducing IGF-I production in bone
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Figure 7: ERK and Akt activation downstream of the IGF-IR
mediates IGF-I stimulation of cell proliferation. Western blot analysis
of H295R cell lysates following 15-minute stimulation with 10 nM
IGF-I in the presence or absence of 1 μM NVP-AEW541 (NVP)
inhibitor of the tyrosine kinase activity of IGF-IR (a). The inhibitor
blocks phosphorylation of Akt (upper panel) and of ERK1/2
(middle panel) both in basal conditions and following IGF-I
stimulation. Lane protein normalization for actin is shown in
the lower panel. Molecular weight markers are indicated. Cell
proliferation was evaluated by MTS assay following 2 or 4 day
stimulation with the indicated treatments (10 nM IGF-I, 20 μM
RGZ, 1 μM NVP) in SW13 (b) or H295R (c) cells, respectively. Mean
± SE percentage of OD over respective control IGF-I taken as 100%.
#P < .001 versus IGF-I, n = 6.
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Figure 8: RGZ does not affect IGF-IR levels. Western blot analysis of
SW13 (a) and H295R (b) cell lysates following 2, 3, and 4 day cell
incubation in the absence (Ctrl) or in the presence of 20 μM RGZ
reveals no significant change in IGF-IR (upper panels). Lane protein
normalization for actin is shown in the lower panels. Molecular
weight markers are indicated. Representative of two independent
experiments.
marrow cells and in the liver [22]. Moreover, troglitazone
inhibits IGF-I tumor-promoting activity in mouse skin by
affecting the intracellular pathway involving AMP kinase
[23].
In SW13 as well as in H295R cells, RGZ was able to
significantly reduce cell proliferation in a dose- and time-
dependent manner as evaluated by different techniques
(MTS, thymidine uptake and cell counting), with a calculated
IC50 of 22.48 ± 1.54μM. This concentration is higher
than the RGZ plasma levels estimated from the total area
under the plasma concentration-time curve (Cmax 1.33 μM)
obtained by pharmacokinetic studies on subjects undergoing
oral RGZ administration with the therapeutical dosage of
8 mg/die [24]. However, it is in perfect agreement with the
doses currently used for in vitro studies, in particular in
cancer cells [10, 16]. Although the RGZ inhibitory effect on
cell proliferation and viability has already been reported in
H295R cells [10, 16], this is the first time that RGZ IC50
and maximal effect have been calculated with an appropriate
statistical analysis [17], thus validating the current dose
of 20 μM used in cancer studies and suggesting that the
anti-proliferative effects of RGZ are obtained at higher
concentrations than the ones effective on insulin sensitivity
[13]. Toxic studies associated with a pharmacokinetic studies
to define the RGZ oral dose capable of resulting in a
range of 20 μM circulating concentration of RGZ and to
10 PPAR Research
investigate the possible toxic effect associated to such doses,
are mandatory in order to hypothesize a possible therapeutic
use of RGZ and other TZD for ACC treatment.
In addition to its effect on cell proliferation in basal
conditions, RGZ was also effective on cell growth induced by
addition of increasing concentrations of IGF-I. Interestingly,
such an inhibitory effect was similar in the presence or in
the absence of IGF-I only in SW13 cells, while in H295R,
RGZ also prevents the stimulatory effect of IGF-I. However,
the inhibitory effect of RGZ was reached more slowly in
H295R (4–7 days) than in SW13 (1-2 days), probably due
to the differences in the kinetic of duplication between
the two cell lines. Moreover, in H295R RGZ inhibition
increases with the dose of IGF-I, while in SW13, the effect
was similar independently of the dose of the growth factor.
Consequently, the IC50 calculated for RGZ curve on SW13
cell proliferation was similar in the presence or absence of
IGF-I.
In order to elucidate at which level RGZ interferes with
the activated IGF-I axis both in basal conditions (IGF-IR
activated by endogenously produced IGF-II) and following
a further activation of the receptor by exogenous addition
of IGF-I, we investigated the signaling pathways acting
downstream of the receptor. RGZ was able to block the rapid
activation of the PI3K-Akt axis induced by IGF-I. In agree-
ment with the experiments on cell proliferation, we found
that in H295R cells only, RGZ was more effective on IGF-I-
treated than on untreated cells. RGZ also affected the ERK
pathway through inhibition of the rapid phosphorylation-
activation of ERK1 and 2 isoforms. A similar effect of RGZ on
rapid phosphorylation of ERKs has been recently described
in the inflammatory response of endothelial cells [14]. Such
an effect is too rapid (15 minutes) to be ascribed to the
classical transactivation mechanism of PPARγ on specific
target genes, and suggests a PPARγ independent mechanism
or a nongenomic activity of the receptor. Interestingly,
among the anticancer action exerted by RGZ in H295R,
both PPARγ dependent and independent effects seem to
coexist in these cells, since the PPARγ antagonist GW9662
has been demonstrated to block RGZ induction of MC2R
expression and cortisol secretion but not RGZ inhibition
of cell proliferation (Betz et al., 2005). Further studies are
required to elucidate the precise mechanism by which PPARγ
ligands affect rapid signaling in these cells. Interestingly, no
effect of RGZ was detected up to 4 day stimulationon the
level of IGF-IR in both cell lines. In accordance, Betz and
colleagues described that IGF-II production increased with
time despite the clear growth-suppressive effects of RGZ and
PIO in H295R [10]. Our findings suggest that RGZ inhibition
acts on the signaling pathways downstream but not at the
level of the IGF-IR.
In conclusion, our result shed new light on the molecular
mechanisms underlying cell proliferation and progression
in adrenal carcinoma, contributing to demonstrate that the
inhibitory effect exerted by RGZ on cell growth is due to
the TDZ interferences with the two main signaling pathways
downstream of the activated IGF-IR. RGZ ability to block
the IGF-IR axis suggests the potential application of this
molecule for the treatment of ACC.
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